Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: oxidation specific epitopes antibodies - Calluna Pharma

Drug Profile

Research programme: oxidation specific epitopes antibodies - Calluna Pharma

Alternative Names: Research programme: OSE antibodies - Calluna Pharma

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxitope Pharma
  • Developer Calluna Pharma
  • Class Analgesics; Antibodies; Antifibrotics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Neuroprotectants
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Age-related macular degeneration; Aortic valve stenosis; Atherosclerosis; Bone disorders; Idiopathic pulmonary fibrosis; Ischaemic heart disorders; Mucocutaneous lymph node syndrome; Myocardial reperfusion injury; Neurodegenerative disorders; Non-alcoholic steatohepatitis; Pain; Respiration disorders; Rheumatoid arthritis

Most Recent Events

  • 23 Jan 2024 Oxitope Pharma has merged with Arxx Therapeutics to form Calluna Pharma
  • 19 Oct 2021 Early research in Mucocutaneous Lymph Node Syndrome in Netherlands (Parenteral)(Oxitope Pharma pipeline, October 2021).
  • 19 Oct 2021 Early research in Pain in Netherlands (Parenteral) (Oxitope Pharma pipeline, October 2021).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top